Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction

Edoardo Spina, Angela Avenoso, Maria Gabriella Scordo, Maria Ancione, Aldo Madia, Giuliana Gatti, Emilio Perucca

Research output: Contribution to journalArticle

Abstract

The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder. Patients stabilized on risperidone (4-6 mg/day) received additional fluoxetine (20 mg/day) to treat concomitant depression. One patient dropped out after 1 week due to the occurrence of akathisia associated with markedly increased plasma risperidone concentrations. In the other subjects, mean plasma concentrations of risperidone increased during fluoxetine administration from 12 ± 9 ng/mL at baseline to 56 ± 31 at week 4 (p <0.001), while the levels of 9-OH-risperidone were not significantly affected. After 4 weeks of combined treatment, the levels of the active moiety (sum of the concentrations of risperidone and 9-OH-risperidone) increased by 75% (range, 9-204%, p <0.01) compared with baseline. The mean plasma risperidone/9-OH-risperidone ratio also increased significantly. During the second week of adjunctive therapy, two patients developed Parkinsonian symptoms, which were controlled with anticholinergic medication. These findings indicate that fluoxetine, a potent inhibitor of the cytochrome P450 enzyme CYP2D6 and a less potent inhibitor of CYP3A4, reduces the clearance of risperidone by inhibiting its 9-hydroxylation or alternative metabolic pathways. This interaction may lead to toxic plasma risperidone concentrations. In addition to careful clinical observation, monitoring plasma risperidone levels may be of value in patients given adjunctive therapy with fluoxetine.

Original languageEnglish
Pages (from-to)419-423
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume22
Issue number4
DOIs
Publication statusPublished - 2002

Fingerprint

Risperidone
Fluoxetine
Drug Interactions
Schizophrenia
Pharmacokinetics
Inhibition (Psychology)
Psychomotor Agitation
Cytochrome P-450 CYP2D6
Poisons
Cholinergic Antagonists
Hydroxylation
Metabolic Networks and Pathways
Psychotic Disorders
Cytochrome P-450 Enzyme System
Therapeutics
Observation
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia : A clinically relevant pharmacokinetic drug interaction. / Spina, Edoardo; Avenoso, Angela; Scordo, Maria Gabriella; Ancione, Maria; Madia, Aldo; Gatti, Giuliana; Perucca, Emilio.

In: Journal of Clinical Psychopharmacology, Vol. 22, No. 4, 2002, p. 419-423.

Research output: Contribution to journalArticle

Spina, Edoardo ; Avenoso, Angela ; Scordo, Maria Gabriella ; Ancione, Maria ; Madia, Aldo ; Gatti, Giuliana ; Perucca, Emilio. / Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia : A clinically relevant pharmacokinetic drug interaction. In: Journal of Clinical Psychopharmacology. 2002 ; Vol. 22, No. 4. pp. 419-423.
@article{e2e700ed074049568b6795abdbf292ee,
title = "Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction",
abstract = "The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder. Patients stabilized on risperidone (4-6 mg/day) received additional fluoxetine (20 mg/day) to treat concomitant depression. One patient dropped out after 1 week due to the occurrence of akathisia associated with markedly increased plasma risperidone concentrations. In the other subjects, mean plasma concentrations of risperidone increased during fluoxetine administration from 12 ± 9 ng/mL at baseline to 56 ± 31 at week 4 (p <0.001), while the levels of 9-OH-risperidone were not significantly affected. After 4 weeks of combined treatment, the levels of the active moiety (sum of the concentrations of risperidone and 9-OH-risperidone) increased by 75{\%} (range, 9-204{\%}, p <0.01) compared with baseline. The mean plasma risperidone/9-OH-risperidone ratio also increased significantly. During the second week of adjunctive therapy, two patients developed Parkinsonian symptoms, which were controlled with anticholinergic medication. These findings indicate that fluoxetine, a potent inhibitor of the cytochrome P450 enzyme CYP2D6 and a less potent inhibitor of CYP3A4, reduces the clearance of risperidone by inhibiting its 9-hydroxylation or alternative metabolic pathways. This interaction may lead to toxic plasma risperidone concentrations. In addition to careful clinical observation, monitoring plasma risperidone levels may be of value in patients given adjunctive therapy with fluoxetine.",
author = "Edoardo Spina and Angela Avenoso and Scordo, {Maria Gabriella} and Maria Ancione and Aldo Madia and Giuliana Gatti and Emilio Perucca",
year = "2002",
doi = "10.1097/00004714-200208000-00014",
language = "English",
volume = "22",
pages = "419--423",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia

T2 - A clinically relevant pharmacokinetic drug interaction

AU - Spina, Edoardo

AU - Avenoso, Angela

AU - Scordo, Maria Gabriella

AU - Ancione, Maria

AU - Madia, Aldo

AU - Gatti, Giuliana

AU - Perucca, Emilio

PY - 2002

Y1 - 2002

N2 - The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder. Patients stabilized on risperidone (4-6 mg/day) received additional fluoxetine (20 mg/day) to treat concomitant depression. One patient dropped out after 1 week due to the occurrence of akathisia associated with markedly increased plasma risperidone concentrations. In the other subjects, mean plasma concentrations of risperidone increased during fluoxetine administration from 12 ± 9 ng/mL at baseline to 56 ± 31 at week 4 (p <0.001), while the levels of 9-OH-risperidone were not significantly affected. After 4 weeks of combined treatment, the levels of the active moiety (sum of the concentrations of risperidone and 9-OH-risperidone) increased by 75% (range, 9-204%, p <0.01) compared with baseline. The mean plasma risperidone/9-OH-risperidone ratio also increased significantly. During the second week of adjunctive therapy, two patients developed Parkinsonian symptoms, which were controlled with anticholinergic medication. These findings indicate that fluoxetine, a potent inhibitor of the cytochrome P450 enzyme CYP2D6 and a less potent inhibitor of CYP3A4, reduces the clearance of risperidone by inhibiting its 9-hydroxylation or alternative metabolic pathways. This interaction may lead to toxic plasma risperidone concentrations. In addition to careful clinical observation, monitoring plasma risperidone levels may be of value in patients given adjunctive therapy with fluoxetine.

AB - The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder. Patients stabilized on risperidone (4-6 mg/day) received additional fluoxetine (20 mg/day) to treat concomitant depression. One patient dropped out after 1 week due to the occurrence of akathisia associated with markedly increased plasma risperidone concentrations. In the other subjects, mean plasma concentrations of risperidone increased during fluoxetine administration from 12 ± 9 ng/mL at baseline to 56 ± 31 at week 4 (p <0.001), while the levels of 9-OH-risperidone were not significantly affected. After 4 weeks of combined treatment, the levels of the active moiety (sum of the concentrations of risperidone and 9-OH-risperidone) increased by 75% (range, 9-204%, p <0.01) compared with baseline. The mean plasma risperidone/9-OH-risperidone ratio also increased significantly. During the second week of adjunctive therapy, two patients developed Parkinsonian symptoms, which were controlled with anticholinergic medication. These findings indicate that fluoxetine, a potent inhibitor of the cytochrome P450 enzyme CYP2D6 and a less potent inhibitor of CYP3A4, reduces the clearance of risperidone by inhibiting its 9-hydroxylation or alternative metabolic pathways. This interaction may lead to toxic plasma risperidone concentrations. In addition to careful clinical observation, monitoring plasma risperidone levels may be of value in patients given adjunctive therapy with fluoxetine.

UR - http://www.scopus.com/inward/record.url?scp=0036328632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036328632&partnerID=8YFLogxK

U2 - 10.1097/00004714-200208000-00014

DO - 10.1097/00004714-200208000-00014

M3 - Article

C2 - 12172343

AN - SCOPUS:0036328632

VL - 22

SP - 419

EP - 423

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 4

ER -